Alzheimer ‘s – Talk Bio

Eli Lilly to Invest Over $1 Billion to Expand Manufacturing Footprint in India

3 weeks ago talkbio0Tagged Alzheimer 's, Autoimmune, contract manufacturing, Diabetes, eli lilly, expansion, Hyderabad, India, Malignant Neoplasms, Manufacturing, Obesity

Eli Lilly; India; manufacturing expansion; contract manufacturing; Hyderabad; pharmaceuticals; obesity; diabetes; Alzheimer’s; cancer; autoimmune

Aerska Launches with $21M to Use Brain ‘Shuttles’ for RNAi Delivery in Neurological Diseases

4 weeks ago talkbio0Tagged Aerska, Alzheimer 's, antibody-oligonucleotide, Blood - brain barrier anatomy, brain shuttles, Gene Silencing, Immunostimulating conjugate (antigen), Irish (ethnic group), Neurological diseases, Parkinson 's, Precision Medicine, RNA Interference

Aerska; Irish biotech; RNA interference (RNAi); brain shuttles; blood-brain barrier; neurological diseases; Alzheimer’s; Parkinson’s; gene silencing; precision medicine; antibody-oligonucleotide conjugates

FDA to Review Lilly’s Alzheimer’s Drug Donanemab in June Advisory Committee Meeting

1 year ago talkbio0Tagged AdCom, Alzheimer 's, Approved, Donanemab, Eli Lilly, Neurodegenerative Disorders, United States Food and Drug Administration

FDA, Lilly, Alzheimer’s, donanemab, June, AdCom, review, approval, treatment, neurodegenerative disease.

Biogen Expands Leqembi Field Force and Launches Omnichannel Campaigns for Next Phase

2 years ago talkbio0Tagged Alzheimer 's, Biogen, expansion, Force Field, launch phase, Leqembi, omnichannel campaigns

Biogen, Leqembi, field force, expansion, omnichannel campaigns, launch phase, Alzheimer’s treatment